Neurological disorders – including Parkinson’s – are leading source of disability globally
Author: Almaz OhenePublished: 16 November 2017
Prep: Cook: Serves:
New research published this week in the journal ‘JAMA Neurology’ by Professor Bastiaan Bloem, from Radboud University Nijmegen Medical Centre in the Netherlands, and Dr Ray Dorsey from University of Rochester Medical Center, shows that neurological disorders are now the leading source of disability worldwide
The medical community must mobilise to respond to the predicted rapid increase in people living with Parkinson’s over the next twenty years, argue leading Parkinson’s specialists Professor Bastiaan Bloem and Dr Ray Dorsey in a journal article this week.
In an article called ‘The Parkinson Pandemic – A Call to Action’ in the journal ‘JAMA Neurology’ earlier this week, the expert physicians point out that between 1990 and 2015, the prevalence of Parkinson’s more than doubled, with an estimated 6.9 million people worldwide living with the condition. They also estimate that by 2040, the number of people with Parkinson’s will increase to 14.2 million as the population ages.
In a bid to combat this growing pandemic, the authors argue that the medical community should pursue the same strategies that transformed HIV from an unknown and fatal illness, into a highly treatable chronic condition.
Dr Ray Dorsey, from the University of Rochester Medical Center, US, said: “Pandemics are usually equated with infectious diseases like Zika, influenza, and HIV – but neurological disorders are now the leading cause of disability in the world and the fastest growing is Parkinson’s disease.”
Their article echoes another study, the ‘Global Burden of Disease’, also co-authored by Dorsey, which appeared in ‘The Lancet Neurology’ in September. That study tracked the prevalence of neurological diseases such as Parkinson’s, Alzheimer’s, stroke, epilepsy, meningitis, encephalitis, multiple sclerosis, and migraine, both globally and by individual country.
Professor Bastiaan Bloem, of the Radboud University NijmegenMedical Centre, the Netherlands, said: “People with HIV infection simply demanded better treatments and successfully rallied for both awareness and new treatments, literally chaining themselves to the doors of pharmaceutical companies. Today, HIV has become a treatable, chronic disease. This upcoming increase in the number of Parkinson’s patients is striking, and frankly, worrisome. We feel it is urgent that people with Parkinson’s go to the pharmaceutical industry and policymakers alike, demanding immediate action to fight this enormous threat.”
Dr Dorsey continued: “For too long the Parkinson’s community has been too quiet on these issues. Building on the AIDS community’s motto of ‘silence equals death’, the Parkinson’s community should make their voices heard. The current and future burden of this debilitating disease depends upon their action.”
The two academics argue that access to care for Parkinson’s – a highly treatable condition – is also limited. In the US for example, more than 40% of individuals with Parkinson’s over the age of 65 do not see a neurologist, while an online survey of 35 European countries showed that 40% of respondents had never seen a Parkinson’s specialist. In less wealthy nations, many are never diagnosed. In a door-to-door study in Bolivia, none of the individuals found to have the condition had ever been diagnosed or received treatment.
Todd Sherer, CEO of The Michael J Fox Foundation, said: “Too many people have Parkinson’s today and more will face diagnoses tomorrow. We all – government, patient organisations, researchers, doctors and patients – must work together for better care for those living with this disease and research toward a future without Parkinson’s.”
Dr Ray Dorsey Dr Ray Dorsey is David M Levy professor of neurology and director of the Center for Health and Technology at the University of Rochester Medical Center, US, where he is helping investigate new treatments for movement disorders and improve the way care is delivered for people with Parkinson and other neurological disorders.
Dr Dorsey previously directed the movement disorders division and neurology telemedicine at Johns Hopkins, Maryland, US. Dr Dorsey’s research has been published in the leading medical, neurology, and economic journals and has been featured in The New York Times, and The Wall Street Journal.
Image credit: University of Rochester Medical Center
Professor Bastiaan Bloem Baastian Bloem is a consultant neurologist at the Department of Neurology, Radboud University Nijmegen Medical Centre, the Netherlands. In 1994, he obtained his PhD degree at the Leiden University Medical Centre, the Netherlands. In 2002, he founded and became medical director of the Parkinson Centre Nijmegen (ParC), the Netherlands, which was recognised from 2005 onwards as centre of excellence for Parkinson’s disease.
Together with Dr Marten Munneke, he also developed ParkinsonNet, where people with Parkinson’s “co-design” their treatment programme in collaboration with a dedicated, multi-disciplinary team – accessed via ParkinsonNet’s online database of expert practitioners.
Innovative remote management gait guidance system is to launch soon
6 days ago
Researchers have finally identified brain cells linked to Parkinson’s disease
For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…
Tiny DBS implant shows potential to advance Parkinson’s disease treatment
In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”
Could a specialised smartwatch support people with Parkinson’s disease?
A specialised smartwatch, which could help those living with Parkinson’s to better manage their condition, will be rolled out to thousands of people in England. The Parkinson’s Kinetigraph, developed by the National Health Service (NHS) in Plymouth and the University of Plymouth, UK, contains sensors designed to monitor the wearer’s activity and buzz with medication reminders. Data collected from the watch – which detects excessive movement, immobility and sleep disturbances – is shared with healthcare providers, allowing for improvements to physiotherapy and prescriptions based on patient needs. Commenting on the smartwatch’s launch, NHS England chief executive Amanda Pritchard said: “Not only is it better for these people living with Parkinson’s, but it is also more efficient for the NHS, freeing up space and time in hospitals for our hard-working staff.” UK health secretary Sajid Javid, meanwhile, described the Kinetigraph as a “fantastic example of how technology is driving cutting-edge innovation…